SM 16

SM 16是有口服活性的TGF-beta I型受体 ( ALK5) 抑制剂。

信号通路 >> 蛋白酪氨酸激酶 >> ALK

研究领域 >> 炎症/免疫

研究领域 >> 癌症

研究领域 >> 心血管疾病

ALK5[1]

[1]. Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9.

[2]. Fu K, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71.

[3]. Engebretsen KV, et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014 Nov;76:148-57.

布格替尼 | 劳拉替尼 | 艾乐替尼 | 恩曲替尼 | NVP-TAE 684 | AZD-3463 | 洛普替尼 | 恩沙替尼(X-376) | 布格替尼 | K02288 | ASP 3026 | CEP-37440 | 2-[[2-[[1-[(二甲基氨基)乙酰基]-5-(甲氧基)-2,3-二氢-1H-吲哚-6-基]氨基]-7H-吡咯并[2,3-d]嘧啶-4-基]氨基]-6-氟-N-甲基苯甲酰胺 | 贝扎替尼